Medindia LOGIN REGISTER
Medindia

Canada withdraws ADHD drug Adderall XR

by Medindia Content Team on Feb 15 2005 3:03 PM

The Canadian authorities Health Canada had suspended the use of the accepted drug Adderall XR for Attention-Deficit Hyperactivity Disorder (ADHD) from the market because of its adverse reports. FDA, the US counterpart of Health Canada has decided to take a wait-and-watch approach. FDA in a press release has asked the parents of children taking Adderall medication to consult their doctors before deciding to stop the medication for their children.

Adderall XR is a stimulant drug prescribed for children diagnosed with ADHD. The drug has been linked with about 20 deaths and ten cases of strokes, some of those affected being children. Although none of the deaths have taken place in Canada, the popular drug has been taken off the markets in Canada.

Federal Drug Administration (FDA) approved Adderall XR, a new variation of the Dexedrine, for ADHD in 1996. Some of the common side effects of this drug are restlessness, lack of sleep, headache, weight loss, mood swings etc. this is the first time death and strokes in patients are being associated with the drug use.

The controversy of Adderall brings into foray once more the long-standing issue for the use of medication in ADHD. While most drugs used in this condition are newly introduced, researchers are still not sure how the long-term results of their use will affect the patients.


Advertisement